Mpex Pharmaceuticals Signs Agreement With Chemical Diversity Labs
CDL to Provide Diverse Compound Collection and Chemistry Services to Support the Discovery of New Antibacterial Agents
02-Oct-2003
Mpex Pharmaceuticals, Inc. ("Mpex") and Chemical Diversity Labs, Inc. ("CDL") announced that they have entered into an agreement where CDL will provide Mpex with a diverse library of 100,000 small molecule compounds to support the discovery of new antibacterial agents. In addition to compound libraries, CDL will also provide various chemistry services to support the optimization of leads identified from the collaboration. Financial terms were not disclosed.
Mpex is pursuing the discovery of next generation antibiotics that meet the growing clinical need created by multi-drug resistant bacterial pathogens. To identify these new agents, Mpex is utilizing its proprietary assay technology to screen new sources of diversity. "CDL has one of the largest sources of diverse chemical compounds," states Bill Gerhart, President and CEO of Mpex. "We believe that their novel diversity will result in promising leads that can be optimized using their extensive chemical synthesis and support capabilities.
"Mpex's unique approach to antibacterial discovery and its proprietary screening technology for membrane protein targets is very appealing," said Ilya Okun, Vice President of Research and Development at CDL. "Although this area is notoriously challenging, we believe that their new screens, in combination with our diverse collection and follow-up chemistry, will enable identification of validated lead compounds."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
